ECG
BMRN icon

Edge Capital Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Edge Capital Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,178
Closed -$309K – 321
2023
Q1 		$309K Buy
+3,178
New +$329K 0.02% 255

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Edge Capital Group's BMRN Position: Q2 2023 in Review

Edge Capital Group sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 3,178 shares — an estimated $309K sold.

Edge Capital Group first reported a position in BMRN in Q1 2023 and held it in 1 quarter. The position peaked at $309K in Q1 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

  • Edge Capital Group reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Edge Capital Group sold 3,178 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $309K.
  • Edge Capital Group first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Edge Capital Group's BioMarin Pharmaceuticals position peaked at $309K in Q1 2023.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Edge Capital Group's 13F filing for Q2 2023, filed 8 Aug 2023.